Ceramedix is a growing, privately- and government- funded biopharmaceutical company developing a new class of endothelial tissue protection and repair medicines pioneered by leading scientific and clinical experts in these areas. Our scientific founders at Memorial Sloan Kettering Cancer Center in New York and our Chief Scientific Officer have formed a deep, mechanistic understanding of a novel signaling biology that drives tissue injury in a broad range of medically relevant settings. We believe our drug candidates will have application for treating multiple disease stresses that lead to organ failure, including those that affect the vascular endothelium of the eye, lung, kidney, and other organs. We are located in New York City.